Albumin infusion therapy in stroke, sepsis and the critically ill

Current Nutrition and Food Science

Volumn 4, Issue 3, 2008, Pages 217-226

  Das, Undurti N ^a  

^a UND LIFE SCIENCES   (United States)

Author keywords

Albumin; Cerebrovascular disease; Critical illness; Cytokines; Docosahexaenoic acid; Free radicals; Interleukins; Lipoxins; Neuroprotectin D1; Neuroprotection; Nitric oxide; Polyunsaturated fatty acids; Reactive oxygen species; Resolvins; Sepsis; Stroke; Superoxide radical; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALBUMINOID; ANTIINFLAMMATORY AGENT; ESSENTIAL FATTY ACID; HETASTARCH; HUMAN ALBUMIN; LIPOXIN; NEUROPROTECTIN D1; PEGYLATED ALBUMIN; RESOLVIN; S NITROSOALBUMIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN MALARIA; CARDIOPULMONARY INSUFFICIENCY; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG INDICATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; FATTY ACID METABOLISM; HUMAN; HYPOALBUMINEMIA; INFLUENZA; INTENSIVE CARE; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SHOCK;

EID: 55249123802     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340108785133329     Document Type: Review

References (74)

1. Wolf PA, Kannel WB, D'Agostino RB. Epidemiology of stroke. In: Ginsberg MD, Bogousslavsky J, Eds. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. Malden, Mass; Blackwell Science 1998: 834-849.
2. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
3. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283: 1151-1158.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
5. Das UN. Critical advances in septicemia and septic shock. Crit Care 2000; 4: 290-294.
6. Vanek V. The use of serum albumin as a prognostic or nutritional marker and the pros and cons of IV albumin therapy. Nutr Clin Pract 1998; 13: 110-22.
7. Uhing MR. The albumin controversy. Clin Perinatol 2004; 31: 475-488.
8. Margarson MP, Soni N. Serum albumin: touchstone or totem? Anaesthesia 1998; 53: 789-803.
9. Doweiko JP, Nompleggi DJ. Role of albumin in human physiology and pathophysiology. J Parenteral Enteral Nutr 1991; 15: 207-211.
10. Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280: 1-8.
11. Albright AL, Latchaw RE, Robinson AG. Intracranial and systemic effects of osmotic and oncotic therapy in experimental cerebral edema. J Neurosurg 1984; 60: 481-489.
12. Foley EF, Borlase C, Dzik WH, Bistrian BR, Benotti PN. Albumin supplementation in the critically ill. A prospective, randomized trial. Arch Surg 1990; 125: 739-742.
13. Dubois MJ, Orellana-Jimenez C, Melot C, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med 2006; 34: 2536-2540.
14. Mendez CM, McClain CJ, Marsano LS. Albumin Therapy in Clinical Practice. Nutr Clin Pract 2005; 20: 314-320.
15. Gines P, Arroyo PV. Is there still a need for albumin infusions to treat patients with liver disease? Gut 2000; 46: 588-590.
16. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48.
17. Golub R, Sorrento JJ Jr, Cantu R Jr, Nierman DM, Moideen A, Stein HD. Efficacy of albumin supplementation in the surgical intensive care unit a prospective, randomized study. Crit Care Med 1994; 22: 613-619.
18. Veneman TF, Oude Nijhuis J, Woittiez AJ. Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial. Wien Klin Wochenschr 2004; 116: 305-309.
19. SAFE Study Investigators, Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 2006; 333: 1044.
20. Gosling P, Brudney S, McGrath L, Riseboro S, Manji M. Mortality prediction at admission to intensive care: a comparison of microalbuminuria with acute physiology scores after 24 hours. Crit Care Med 2003; 31: 98-103.
21. Roe PG. Liver function tests in the critically ill patients. Clin Intensive Care 1993; 4: 174-182.
22. Gough DB, White M, Morrin M, et al. The relationship between a nutritional index and acute physiology score in critical illness. Irish J Med Sci 1992; 161: 565-568.
23. Dofferhoff AS, Bom VJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20: 185-192.
24. Das UN. Lysophosphatidylcholine and ω-3 fatty acids in sepsis. Adv Sepsis 2004; 3: 121-128.
25. Das UN. Can critical illness and sepsis be predicted or prognosticated? Adv Sepsis 2006; 5: 52-59.
26. Das UN. Ethyl pyruvate in sepsis. Adv Sepsis 2007; 6: 10-15.
27. Das UN. Cytokines, NF-kB, activated protein C, oxidized phospholipids, inducible cyclo-oxygenase eicosanoids, adenosine and insulin in sepsis and septic shock. Crit Care Shock 2003; 6: 40-49.
28. Das UN. Current advances in sepsis and septic shock with particular emphasis on the role of insulin. Med Sci Monit 2003; 9: RA181-RA192.
29. Das UN. Insulin in sepsis and septic shock. J Assoc Physicians India 2003; 51: 695-700.
30. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 1997; 87: 595-601.
31. Belayev L, Zhao W, Pattany PM, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 1998; 29: 2587-2599.
32. Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res 1998; 804: 105-113.
33. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001; 32: 553-560.
34. Remmers M, Schmidt-Kastner R, Belayev L, Lin B, Busto R, Ginsberg MD. Protein extravasation and cellular uptake after high-dose human-albumin treatment of transient focal cerebral ischemia in rats. Brain Res 1999; 827: 237-242.
35. Belayev L, Saul I, Huh PW, et al. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Res 1999; 845: 107-111.
36. Belayev L, Alonso OF, Huh PW, Zhao W, Busto R, Ginsberg MD. Post-treatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J Neurotrauma 1999; 16: 445-453.
37. Loeb MR. Unexpected effects of absorbed normal rabbit serum and bovine serum albumin on survival of Haemophilus influenzae type b in the infant rat. Microb Pathog 1988; 4: 9-13.
38. Gluckman TL, Grossman JE, Folts JD, Kruse-Elliott KT. Modulation of endotoxin-induced cardiopulmonary dysfunction by S-nitroso-albumin. J Endotoxin Res 2002; 8: 17-26.
39. Powers KA, Kapus A, Khadaroo RG, Marshall JC, Lindsay TF, Rotstein OD. Twenty-five percent albumin prevents lung injury following shock/ resuscitation. Crit Care Med 2003; 31: 2355-2363.
40. Zhang H, Voglis S, Kim CH, Slutsky AS. Effects of albumin and Ringer's lactate on production of lung cytokines and hydrogen peroxide after resuscitated hemorrhage and endotoxemia in rats. Crit Care Med 2003; 31: 1515-1522.
41. Assaly RA, Azizi M, Kennedy DJ, et al. Plasma expansion by polyethylene-glycol-modified albumin. Clin Sci (Lond) 2004; 107: 263-272.
42. Tokunaga C, Bateman RM, Boyd J, Wang Y, Russell JA, Walley KR. Albumin resuscitation improves ventricular contractility and myocardial tissue oxygenation in rat endotoxemia. Crit Care Med 2007; 35: 1341-1347.
43. Walley KR, McDonald TE, Wang Y, Dai S, Russell JA. Albumin resuscitation increases cardiomyocyte contractility and decreases nitric oxide synthase II expression in rat endotoxemia. Crit Care Med 2003; 31: 187-194.
44. Hangai-Hoger N, Nacharaju P, Manjula BN, et al. Microvascular effects following treatment with polyethylene glycol-albumin in lipopolysaccharide-induced endotoxemia. Crit Care Med 2006; 34: 108-117.
45. Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 1989; 17: 394-398.
46. Byrne K, Tatum JL, Henry DA, et al. Increased morbidity with increased pulmonary albumin flux in sepsis-related adult respiratory distress syndrome. Crit Care Med 1992; 20: 28-34.
47. Cochran A, Morris SE, Edelman LS, Saffle JR. Burn patient characteristics and outcomes following resuscitation with albumin. Burns 2007; 33: 25-30.
48. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-2256.
49. Choi DW. Excitotoxic cell death. J Neurobiol 1992; 23: 1261-1276.
50. Tymianski M. The central role of calcium ions and calcium-permeable channels in ischemic brain injury. In: Ginsberg MD, Bogousslavsky J, Eds. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. Malden, Mass; Blackwell Science 1998: 371-390.
51. Chan H. Role of oxidants in ischemic brain damage. Stroke 1996; 27: 1124-1129.
52. Feuerstein GZ, Wang X, Barone FC. The role of cytokines in the neuropathology of stroke and Neurotrauma. Neuroimmunomodulation 1998; 5: 143-159.
53. Rodriguez de Turco EB, Belayev L, Liu Y, et al. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotective therapy with human albumin. J Neurochem 2002; 83: 515-524.
54. Bazan NG. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In: Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain. New York; Raven Press; 1990.
55. Das UN. Essential fatty acids: Biochemistry, physiology, and pathology. Biotechnol J 2006; 1: 420-439.
56. Das UN. Essential fatty acids- a review. Curr Pharm Biotechnol 2006; 7: 467-482.
57. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995; 92: 9475-9479.
58. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999; 104: 309-316.
59. Serhan CN, Hong S, Gronert K, et al. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025-1037.
60. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278: 43807-43817.
61. Hong S. Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and- glial cells. Autacoids in anti-inflammation. J Biol Chem 2003; 278: 14677-14687.
62. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101: 8491-8496.
63. Gronert K, Maheshwari N, Khan N, Hasan IR. Dunn M, Laniado Schwartzman M. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 2005; 280: 15267-15278.
64. Calon F, Lim GP. Yang F, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43: 633-645.
65. Lukiw WJ, Cui J-G, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-2783.
66. Belayev L, Marcheselli VL, Khoutorova L, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005; 36: 118-123.
67. Das UN. Biological significance of essential fatty acids. J Assoc Physicians India 2006; 54: 309-319.
68. Akech S, Gwer S. Idro R, et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: result of a controlled trial. PLoS Clin Trials 2006; 1: e21.
69. He P, Curry FE. Albumin modulation of capillary permeability: role of endothelial cell [Ca2+]i. Am J Physiol 1993; 265: H74-H82.
70. Koch S, Concha M, Wazzan T, Romano JG, Forteza A. High dose human serum albumin for the treatment of acute ischemic stroke: A safety study. Neurocrit Care 2004; 1: 335-341.
71. Osband AJ, Sifri ZC, Wang L, et al. Small volume albumin administration protects against hemorrhagic shock-induced bone marrow dysfunction. J Trauma 2004; 56: 279-283.
72. Li WQ, Wang XY, Zhu H, et al. Albumin kinetics in patients with severe sepsis. Zhonghua Wai Ke Za Zhi 2003; 41: 423-426.
73. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D. The ALIAS Pilot Trial. A dose-escalation study of albumin therapy for acute ischemic stroke-I: physiological response and safety results. Stroke 2006; 37: 2100-2106.
74. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD. The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: neurologic outcome and efficacy analysis. Stroke 2006; 37: 2107-2114.